Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Abbvie CDR ABBV


Primary Symbol: T.ABBV

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for...


TSX:ABBV - Post by User

<< Previous
Bullboard Posts
Next >>
User Avatar Image
(11)
•••
  • WrywisdomX
Post by Wrywisdomon Aug 10, 2022 3:21pm
389 Views
Post# 34886025

Incredible Value. ENTG at about 25% of One Years Revenue

Incredible Value. ENTG at about 25% of One Years Revenue.with revenues now demonstrating an upward Trajectory amd likely attaining profitability within a couple of quarters. May reportage for example indicates record first quarter 2022 results:

                   https://stockhouse.com/news/press-releases/2022/05/30/entourage-health-reports-record-first-quarter-2022-financial-results

Notwithstanding all of the prior major achievements getting us to this point, just within the past few weeks:

           -unlike so many cannabis counterparts, ENTG has shored up high level financing guaranteed for more than 2 years with no dilution, and dramatically reduces convertible debentures:

                   https://stockhouse.com/news/press-releases/2022/07/29/entourage-health-provides-update-on-credit-facilities-maturity-dates-and-amends

           -Further expands medical offerings with new products and services:

                   tockhouse.com/news/press-releases/2022/07/26/entourage-expands-medical-offerings-with-launch-of-new-services-and-products

          -Announces and exclusive Canadian licensing deal to distribute a broad range of Irwin Naturals cannabis Products:

                   https://stockhouse.com/news/press-releases/2022/08/04/irwin-naturals-cannabis-products-to-be-available-in-canada

          
...and will be introducting groundbreaking Boston Beer/Samuel Adams products at any time now:
            https://stockhouse.com/news/press-releases/2022/05/23/the-boston-beer-company-introduces-teapot-a-new-line-of-cannabis-infused-iced

         
Simply an unrivaled value, period. 
What a truly extraordinary opportunity here particularly for new investors but again, also for those seeking to cost average as well.
<< Previous
Bullboard Posts
Next >>